Comparison of clinical and laboratory characteristics of MDS patients responding and not responding to ATRA plus EPO treatment
| . | Responders (range) . | Nonresponders (range) . | P . |
|---|---|---|---|
| Median age, y | 66 (54-77) | 69 (52-78) | .319 330 |
| M/F | 6/7 | 7/7 | 1.000 000 |
| MDS duration, mo | 22 (12-56) | 25 (8-55) | .644 601 |
| Serum EPO | 322 (80-1115) | 467 (125-1482) | .468 262 |
| Prior RBC transfusion requirements, U/mo | 2 (0-4) | 2.5 (0-4) | .507 629 |
| Hb levels, g/dL | 7.9 (6.7-9.3) | 8.1 (6.1-9.5) | .884 009 |
| Reticulocytes, × 109/L | 22.33 (5.9-80.0) | 18.89 (4.86-86.3) | .752 408 |
| ANC, × 109/L | 2.4 (0.5-3.7) | 1.55 (0.9-4.1) | .144 909 |
| Platelets, × 109/L | 104 (32-220) | 133.5 (67-298) | .528 024 |
| Cytogenetics, normal/abnormal | 5/4 | 7/3 | .649 920 |
| . | Responders (range) . | Nonresponders (range) . | P . |
|---|---|---|---|
| Median age, y | 66 (54-77) | 69 (52-78) | .319 330 |
| M/F | 6/7 | 7/7 | 1.000 000 |
| MDS duration, mo | 22 (12-56) | 25 (8-55) | .644 601 |
| Serum EPO | 322 (80-1115) | 467 (125-1482) | .468 262 |
| Prior RBC transfusion requirements, U/mo | 2 (0-4) | 2.5 (0-4) | .507 629 |
| Hb levels, g/dL | 7.9 (6.7-9.3) | 8.1 (6.1-9.5) | .884 009 |
| Reticulocytes, × 109/L | 22.33 (5.9-80.0) | 18.89 (4.86-86.3) | .752 408 |
| ANC, × 109/L | 2.4 (0.5-3.7) | 1.55 (0.9-4.1) | .144 909 |
| Platelets, × 109/L | 104 (32-220) | 133.5 (67-298) | .528 024 |
| Cytogenetics, normal/abnormal | 5/4 | 7/3 | .649 920 |